Comparing the current results to its competitors, Sana Biotechnology Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 16.41 %, recorded in the same quarter.
Sana Biotechnology Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment with other firms developing cell and gene therapies targeting type 1 diabetes, oncology, and B cell-mediated autoimmune disorders. Competitors include AbbVie Inc., Allogene Therapeutics, Inc., Aspect Biosystems Ltd., AstraZeneca PLC, Bristol-Myers Squibb Company, Cabaletta Bio, Inc., Caribou Biosciences, Inc., Century Therapeutics, Inc., CRISPR Therapeutics AG, Eli Lilly and Company, Gilead Sciences, Inc., Johnson & Johnson, Kelonia Therapeutics, Inc., Kyverna Therapeutics, Inc., Legend Biotech Corporation, Novartis AG, Roche Holding AG, Umoja Biopharma, Inc., and Vertex Pharmaceuticals Inc. Some of these competitors have greater financial resources, larger research and development teams, and established marketing and sales operations. Additionally, certain competitors operate in jurisdictions with lower standards of evidence for product approval. Several are conducting clinical trials for therapies that may compete with the company’s ex vivo and in vivo programs. The company also faces uncertainties related to patent protection and the potential for competitors to independently develop similar technologies, which could affect its competitive position.
April 12, 2025
NEW YORK, April 12, 2025 Pomerantz LLP has announced the filing of a class action lawsuit against Sana Biotechnology, Inc. (NASDAQ: SANA) and certain top executives amidst growing scrutiny surrounding the company’s financial performance. The case, filed in the United States District Court for the Western District of Washington and docketed under number 25cv00512, claims that the defendants violated federal securities laws, seeking damages for a class of investors who purchased or acquired Sana securities between March 17, 2023, and November 4, 2024.The action arises from substantial concerns over Sana’s financial health, particularly its recent disclosure of a cumulative net loss of $267 million for t...
Sana Biotechnology, a leading biotechnology company, presented groundbreaking preclinical data at the American Society of Hematology Annual Meeting, shedding light on the remarkable abilities of their hypoimmune-modified allogeneic CAR T cells. These findings have further strengthened the completed IND submission for SC262, a HIP-modified CD22-directed allogeneic CAR T cell, propelling the field of immunotherapy towards a new era of cancer treatment. Immunotherapy has revolutionized the way we approach cancer treatment, harnessing the body s own immune system to fight against malignant cells. Chimeric Antigen Receptor (CAR) T cell therapy, in particular, has shown remarkable success in the trea...
Editas Medicine Inc.'s business model revolves around developing and commercializing transformative genome editing technologies to treat serious diseases.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Sources:
Sana Biotechnology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sana Biotechnology Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
